|Dr. Phillip P. Chan M.D., Ph.D.||CEO & Director||667.47k||N/A||1970|
|Mr. Vincent J. Capponi M.S., MS||Pres & COO||539.29k||N/A||1958|
|Ms. Kathleen P. Bloch CPA, CPA, M.B.A., MBA||CFO & Sec.||462.11k||N/A||1955|
|Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.||Chief Medical Officer||521.61k||N/A||1969|
|Ms. Terri Anne Powers M.B.A.||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Dr. Christian Steiner M.D.||Exec. VP of Sales & Marketing||N/A||N/A||N/A|
|Mr. Christopher Cramer MBA, MS||VP of Bus. Devel.||N/A||N/A||N/A|
|Dr. Robert H. Bartlett M.D.||Co-Chairman of Cardiac Surgery Advisory Board & Consultant||N/A||N/A||1939|
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Cytosorbents Corporation’s ISS Governance QualityScore as of November 28, 2022 is 7. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 3; Compensation: 8.